Biogen Idec, Inc. (BIIB)
$46.38
0.53 (+1.16%)
| CAPS Rating |
|
|---|---|
| Open | $45.60 |
| Previous Close | $45.85 |
| Daily Range | $45.56 - $46.52 |
| 52-Week Range | $37.21 - $55.34 |
| Market Cap | $13.41B |
| P/E Ratio | 15.28 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 2,829,055 |
| Average Daily Volume | 4,339,000 |
BIIB
VS S&P 500 (SPY)
How do you think BIIB will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BIIB Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BIIB News and Commentary
- UPDATE: HealthCor Urges Biogen Board Consider Number Of Changes – SmartMoney
- UPDATE 1-HealthCor slams Biogen CEO for outsize pay package – Reuters
- HealthCor Urges Biogen Board Consider Number Of Changes – SmartMoney
- This Stock Is a Train Wreck – The Motley Fool
- UPDATE: Icahn Reports New Stakes In Genzyme, Forest Labs – SmartMoney
- Icahn Reports New Stakes In Genzyme, Forest Labs At Sept 30 – SmartMoney
- Abbott: Brave or Stupid? – The Motley Fool
- CNBC on Biogen IDEC, Inc. – Ockham-RazorWire
- Experts Tell FDA Not To Expect Too Much From Drug Ads On Web – SmartMoney
- Biogen Rethinking Disclosure Policies On MS Drug Tysabri – SmartMoney
- 2nd UPDATE: Biogen, Elan, Roche In Brain Infection Consortium – SmartMoney
- 4-Star Stocks on the Upswing – The Motley Fool
- Nice Quarter, Teva. What Will You Buy Next? – The Motley Fool
- 10 Stocks Shaking the Market – The Motley Fool
- Finally Convinced? Benlysta Works! – The Motley Fool
- Earnings? Yawn. Trial Data? Moving! – The Motley Fool
- Don't Make This Humongous Life-Wrecking Error – The Motley Fool
- 3 Stocks in a Tailspin – The Motley Fool
- UPDATE 1-EU agency reports 24th case of Tysabri infection – Reuters
- For Tysabri, 23 Is 10 Too Many – The Motley Fool
RSS Headlines
Fool UK
